Skip to content
The People's CodeSearch
Menu

Changes to the Code

S. 3019 · No Big Blockbuster Bailouts Act ·

In committee · step 2 of 5

Sections are cited like “7 U.S.C. § 2012”: 7 of the , 2012.

42 U.S.C. § 1320f–1 Selection of negotiation-eligible drugs as selected drugs

+10 −123 of 5 shown
More for 42 U.S.C. § 1320f–1
Read § 1320f–1Only this section
5 changes the bill asks for here, 3 carried out
  1. Not carried out:

    in paragraph (1), in the matter preceding subparagraph (A), by striking through (4) and inserting and (3);

    “through (4)” isn't in § 1320f–1(e)(1) in the Code as we have it. The law may have changed since the bill was drafted.

    Technical detail“through (4)” not found in /us/usc/t42/s1320f–1/e/1
  2. Carried out:

    by striking subparagraph (A);

  3. Carried out:

    by redesignating subparagraphs (B) and (C) as subparagraphs (A) and (B), respectively; and

  4. Carried out:

    in subparagraph (A)(iii), as redesignated by subparagraph (B) of this paragraph, by striking with respect to and inserting subject to paragraph (4), with respect to; and

  5. Not carried out:

    by striking paragraph (4) and inserting the following new paragraph:(4) Treatment of orphan drugs.— In the case of a drug that is designated as a drug for one or more rare diseases or conditions and for which the only approved indication (or indications) is for one or more such rare diseases or conditions (as such term is defined in section …

    The bill points to paragraph (4) of § 1320f–1(e), which isn't there in the Code as we have it. It may have been renumbered or removed since the bill was drafted.

    Technical detailno paragraph (4) in /us/usc/t42/s1320f–1/e

§ 1320f–1(e)–(f)

Start of § 1320f–1 to (e)(2)(B)(ii)(I) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(e)(2)(B)(ii)(II)(II) (II)
is marketed, sold, or distributed directly or indirectly to retail class of trade under a different labeling, packaging (other than repackaging as the reference product in blister packs, unit doses, or similar packaging for use in institutions), product code, labeler code, trade name, or trade mark than the reference product.is marketed, sold, or distributed directly or indirectly to retail class of trade under a different labeling, packaging (other than repackaging as the reference product in blister packs, unit doses, or similar packaging for use in institutions), product code, labeler code, trade name, or trade mark than the reference product.
(e)(3)(3) Exclusions(3) Exclusions
In this part, the term “qualifying single source drug” does not include any of the following:In this part, the term “qualifying single source drug” does not include any of the following:
(e)(3)(A)(A) [struck: Certain orphan drugs]
[struck: A drug that is designated as a drug for only one rare disease or condition under section 360bb of title 21 and for which the only approved indication (or indications) is for such disease or condition.]
[struck: (B)] Low spend medicare drugs[inserted: (A)] Low spend medicare drugs
A drug or biological product with respect to which the total expenditures under parts B and D of subchapter XVIII, as determined by the Secretary in accordance with subsection (d)(3)(B)—A drug or biological product with respect to which the total expenditures under parts B and D of subchapter XVIII, as determined by the Secretary in accordance with subsection (d)(3)(B)—
(e)(3)(A)(i)(i) (i)
with respect to initial price applicability year 2026, is less than, during the period beginning on June 1, 2022, and ending on May 31, 2023, $200,000,000;with respect to initial price applicability year 2026, is less than, during the period beginning on June 1, 2022, and ending on May 31, 2023, $200,000,000;
(e)(3)(A)(ii)(ii) (ii)
with respect to initial price applicability year 2027, is less than, during the most recent 12-month period applicable under subparagraphs (A) and (B) of subsection (d)(1) for such year, the dollar amount specified in clause (i) increased by the annual percentage increase in the consumer price index for all urban consumers (all items; United States city average) for the period beginning on June 1, 2023, and ending on September 30, 2024; orwith respect to initial price applicability year 2027, is less than, during the most recent 12-month period applicable under subparagraphs (A) and (B) of subsection (d)(1) for such year, the dollar amount specified in clause (i) increased by the annual percentage increase in the consumer price index for all urban consumers (all items; United States city average) for the period beginning on June 1, 2023, and ending on September 30, 2024; or
(e)(3)(A)(iii)(iii) (iii)
with respect to a subsequent initial price applicability year, is less than, during the most recent 12-month period applicable under subparagraphs (A) and (B) of subsection (d)(1) for such year, the dollar amount specified in this subparagraph for the previous initial price applicability year increased by the annual percentage increase in such consumer price index for the 12-month period ending on September 30 of the year prior to the year of the selected drug publication date with respect to such subsequent initial price applicability year.[inserted: subject to paragraph (4), ]with respect to a subsequent initial price applicability year, is less than, during the most recent 12-month period applicable under subparagraphs (A) and (B) of subsection (d)(1) for such year, the dollar amount specified in this subparagraph for the previous initial price applicability year increased by the annual percentage increase in such consumer price index for the 12-month period ending on September 30 of the year prior to the year of the selected drug publication date with respect to such subsequent initial price applicability year.
(e)(3)(B)[struck: (C)] Plasma-derived products[inserted: (B)] Plasma-derived products
A biological product that is derived from human whole blood or plasma.A biological product that is derived from human whole blood or plasma.
(f)(f) Special rule to delay selection and negotiation of biologics for biosimilar market entry(f) Special rule to delay selection and negotiation of biologics for biosimilar market entry
(f)(1)(1) Application(1) Application
(f)(1)(A)(A) In general(A) In general
Subject to subparagraph (B), in the case of a biological product that would (but for this subsection) be an extended-monopoly drug (as defined in section 1320f–3(c)(4) of this title) included as a selected drug on the list published under subsection (a) with respect to an initial price applicability year, the rules described in paragraph (2) shall apply if the Secretary determines that there is a high likelihood (as described in paragraph (3)) that a biosimilar biological product (for which such biological product will be the reference product) will be licensed and marketed under section 262(k) of this title before the date that is 2 years after the selected drug publication date with respect to such initial price applicability year.Subject to subparagraph (B), in the case of a biological product that would (but for this subsection) be an extended-monopoly drug (as defined in section 1320f–3(c)(4) of this title) included as a selected drug on the list published under subsection (a) with respect to an initial price applicability year, the rules described in paragraph (2) shall apply if the Secretary determines that there is a high likelihood (as described in paragraph (3)) that a biosimilar biological product (for which such biological product will be the reference product) will be licensed and marketed under section 262(k) of this title before the date that is 2 years after the selected drug publication date with respect to such initial price applicability year.

Rest of § 1320f–1 unchanged

Step through the changes